# **Morning Glance**



## **Equity Research Desk**

Indices	Value	Change (Pts)	Change (%)
Nifty 50	25,405.3	-48.1	-0.19%
BSE Sensex	83,239.5	-170.2	-0.20%
GIFT Nifty*	25,507.5	+12.5	+0.05%
Dow Jones	44,828.53	344.11	0.77%
S&P 500	6,279.35	51.93	0.83%
NASDAQ	20,601.10	207.97	1.02%
FTSE 100	8,823.20	48.51	0.55%
CAC 40	7,754.55	16.13	0.21%
DAX	23,934.1	144.0	0.61%
Shanghai*	3,460.0	-1.2	-0.03%
Nikkei 225*	39,836.63	50.73	0.13%
Hang Seng*	23,759.5	-310.4	-1.29%

#### \*As at 8.00 am

Commodity	Price (USD)	Change (Pts)	Change (%)
Oil (WTI)	66.9	-0.3	-0.42%
Oil (Brent)	68.6	-0.3	-0.36%
Gold	3,330.3	3.8	0.11%
Silver	36.7	-0.2	-0.43%
Copper	10,120.0	75.0	0.75%
Cotton	0.68	0.00	0.58%

Currency	Value	Change (Pts)	Change (%)
EUR/USD	1.18	0.00	-0.39
USD/INR	85.31	-0.40	-0.47
GBP/INR	116.53	-0.82	-0.70
EUR/INR	100.57	-0.31	-0.30
DXY Index	96.80	0.03	0.03

VIX	Value	Change (Pts)	Change (%)
India VIX	12.39	-0.06	-0.48%
S&P 500 VIXApr 24	16.38	-0.26	-1.56%

Indicators	Value (%)	Change (Bps)
India 10-Year Yield	6.345	0.000
US 10-Year Yield	4.265	-0.018

### **Market Updates**

The markets are expected to open marginally higher today as trends in GIFT NIFTY indicate a positive start for the broader index after NIFTY closed 48 points lower at 25,405 on Thursday.

### **Aegis Logistics**

The company commissioned a 48,000 MT LPG cryogenic terminal at Pipavav for storage and terminalling on behalf of associate Aegis Vopak.

#### **Biocon**

The company's subsidiary Biocon Biologics received EU approval for Denosumab biosimilars Vevzuo and Evfraxy for osteoporosis and bone-related cancer conditions.

#### **Godrej Industries**

The company's chemicals business will invest over ₹750 crore to expand capacities across key products and boost renewable energy use to 75%.

#### **Indian Energy Exchange**

The company achieved 10,852 MU trade in June'25 ( $\uparrow$ 6.5% YoY) and 32,382 MU in Q1 FY'26 ( $\uparrow$ 15% YoY), with REC trade, RTM, and Green Market volumes rising sharply, while DAM prices fell on lower summer demand and higher supply.

#### **IndiGrid**

The company partnered with IFC to develop a 180 MW/360 MWh battery storage project in Gujarat with ₹460 crore IFC funding support.

#### **Kaynes Technology**

The company approved a \$17.7 million further investment in Singapore-based subsidiary Kaynes Holding for business expansion and strategic acquisitions.

#### **NBCC**

The company secured ₹65.73 crore orders including ₹43.9 crore from RGIPT and ₹21.83 crore from NVS, and signed MoU to redevelop Siri Fort Auditorium, New Delhi.

#### **ONGC**

The company signed a Heads of Agreement with Mitsui O.S.K. Lines to build, own, and operate two VLECs for supplying ethane to OPaL.

#### **Tata Power**

The company's subsidiary TPREL commissioned a record 752 MW solar capacity in Q1 FY26, raising total utility-scale ops to 5.6 GW.

#### **Uno Minda**

The company, via subsidiary UnoMinda EV Systems, completed acquisition of Germany-based e-drive business assets and IP from Friwo Group.

#### **Vedanta**

The company reported Q1FY26 production with record alumina at 587 kt, up 9% YoY and 36% QoQ, Zinc Int'l mined metal up 50% YoY and 12% QoQ, Ferro Chrome up 150% QoQ, and power sales at 4,289 MU, up 11% QoQ.

# **Morning Glance**



## **Equity Research Desk**

#### **Disclaimers & Disclosures**

Analyst Certification of Independence: The analysts(s) for this report certifies that all the views expressed in this report accurately reflect his or her personal views about the subject company(ies) or issuers and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Arete Securities. Limited, and have no bearing whatsoever on any recommendation that they have given in the Research Report. Disclaimer and Disclosures as required under SEBI (Research Analyst) Regulations, 2014: Arete Securities Limited, have no bearing whatsoever on any recommendation that they have given in the Research Report. Disclaimer and Disclosures as required under SEBI (Research Analyst) Regulations, 2014: Arete Securities Limited (hereinafter refer as Arete Securities) and insurance broking. Arete Securities are securities broking company having membership of NSE, BSE & MSEI for Equity, Future & Option, Currency Derivatives segment and Wholesale Debt Market. The Company is focused primarily on providing securities broking services to institutional clients and is empanelled as an approved securities broker with all the major Nationalised, Private and Co-operative banks, Corporate houses, Insurance Companies, Financial Institutions, Asset Management Companies and Provident Fund Trusts. Details of affiliates are available on our website i.e. www.spasec.in

Arete Securities Limited is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014. Vide SEBI Reg. No. INH00002615.

We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in the last five years. We have n

would enleave to update the information relation that are subject to change without notice.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

This Research Report should be read and relied upon at the sole discretion and risk of the recipient. If you are dissatisfied with the contents of this complimentary Research Report or with the terms of this Disclaimer, your sole and exclusive remedy is to stop using this Research Report. Neither Arete Securities nor its affiliates or their respective directors, employees, agents or representatives shall be responsible or liable in any manner, directly or indirectly, for the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the process of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

reduction in the dividend or income, etc.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Arete Securities may have issued other reports in the past that are inconsistent with and reach different conclusion from the information presented in this report.

Arete Securities, its affiliates and employees may, from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other services for solicit investment banking or other services fo

India before investing in the Indian Markets.

A graph of daily closing prices of securities is available at www.nseindia.com and http://economictimes.indiatimes.com/markets/stocks/stock-quotes. (Choose a company from the list on the browser and select the "three years" icon in the

Agriph or daily costing prices of securities as described to the country of the price charty.

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, reproduction, availability or use would be contrary to law or regulation or what would subject Arete Securities or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently send or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes without prior written approval of Arete Securities.

List of Associates as per SEBI (Research Analyst) Regulations, 2014

Statements on ownership and material conflicts of interest, compensation - Arete and Associates

Disclosure of interest statement	Yes/No
Arete Securities/its Affiliates/Analyst/his or her Relative financial interest in the company	No
Arete Securities/its Affiliates/Analyst/his or her Relative actual/beneficial ownership of more than 1% in subject company at the end of the month. Immediately preceding the date of the publication of the research report or date of public appearance.	No
Investment banking relationship with the company covered	No
Any other material conflict of interest at the time of publishing the research report	No
Receipt of compensation by Arete Securities or its Affiliated Companies from the subject company covered for in the last twelve months:	
Managing/co-managing public offering of securities	
Investment banking/merchant banking/brokerage services	
products or services other than those above	No
in connection with research report	
Whether Research Analyst has served as an officer, director or employee of the subject company covered	No
Whether the Research Analyst or Research Entity has been engaged in market making activity of the Subject Company;	No

For statements on ownership and material conflicts of interest, compensation, etc. for individual Research Analyst(s), please refer to each specific research report.

ARETE Securities Ltd: Mittal Court, A-Wing, 10th Floor, Nariman Point, Mumbai - 400 021, Tel. No.: +91-022-4289 5600, Fax: +91 (22) 2657 3708/9

ARETE SECURITIES LTD.

ARETE SECURITIES LTD	SEBI REG. NOS.
NSE Capital Market	INZ000241036
NSE Future & Option	INZ000241036
NSE Currency Derivatives	INZ000241036
NSE Future & Option	INZ000241036
BSE Cash	INZ000241036
BSE Wholesale Debt Market	INZ000241036
BSE Currency Derivatives	INZ000241036
NSDL DP	DP ID IN303680
Research Analyst	INH100002615
Merchant Banker	INM000012740
Investment Advisor	INA000014614